Creatine phosphokinase in long-term dialysis patients

1981 ◽  
Vol 141 (2) ◽  
pp. 181-188 ◽  
Author(s):  
O. Soffer
Keyword(s):  
Creatine Phosphokinase ◽  
Dialysis Patients

scholarly journals SP507FACTORS AFFECTING LONG TERM TECHNIQUE SURVIVAL OF PERITONEAL DIALYSIS PATIENTS

2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii546-iii547
Author(s):  
Marios Theodoridis ◽  
Stylianos Panagoutsos ◽  
Eleni Triantafyllidou ◽  
Pelagia Kriki ◽  
Konstantia Kantartzi ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Dialysis Patients ◽  
Technique Survival

scholarly journals Long-term Survival of Dialysis Patients With Bacterial Endocarditis Undergoing Valvular Replacement Surgery in the United States

Circulation ◽  
2013 ◽  
Vol 128 (4) ◽  
pp. 344-351 ◽  
Author(s):  
Maxwell D. Leither ◽  
Gautam R. Shroff ◽  
Shu Ding ◽  
David T. Gilbertson ◽  
Charles A. Herzog
Keyword(s):  
United States ◽  
The United States ◽  
Bacterial Endocarditis ◽  
Dialysis Patients ◽  
Term Survival ◽  
Long Term Survival ◽  
Replacement Surgery ◽  
Valvular Replacement

Can radiological assessment of abdominal computerized scans diagnose encapsulating peritoneal sclerosis in long-term peritoneal dialysis patients?

Nephrology ◽  
2016 ◽  
Vol 22 (1) ◽  
pp. 19-24 ◽  
Author(s):  
Sam Stuart ◽  
David Stott ◽  
Antony Goode ◽  
Charlotte J Cash ◽  
Andrew Davenport
Keyword(s):  
Peritoneal Dialysis ◽  
Radiological Assessment ◽  
Dialysis Patients

Early and long-term results of coronary artery bypass grafting in dialysis patients

2000 ◽  
Vol 70 (3) ◽  
pp. 813-818 ◽  
Author(s):  
Dion L Franga ◽  
John M Kratz ◽  
A.Jackson Crumbley ◽  
James L Zellner ◽  
Martha R Stroud ◽  
...  
Keyword(s):  
Coronary Artery ◽  
Coronary Artery Bypass Grafting ◽  
Coronary Artery Bypass ◽  
Artery Bypass ◽  
Long Term Results ◽  
Bypass Grafting ◽  
Dialysis Patients ◽  
Artery Bypass Grafting

Beta-2-Microglobulin Amyloidosis in Long-Term Dialysis Patients

1989 ◽  
Vol 9 (3) ◽  
pp. 177-183 ◽  
Author(s):  
William J. Stone ◽  
Raymond M. Hakim
Keyword(s):  
Dialysis Patients ◽  
Beta 2 ◽  
Beta 2 Microglobulin

scholarly journals Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients

2021 ◽  
Vol 11 (1) ◽  
pp. 64
Author(s):  
Noa Berar-Yanay ◽  
Sarit Freiman ◽  
Maʹanit Shapira ◽  
Amer Saffoury ◽  
Ameer Elemy ◽  
...  
Keyword(s):  
Response Rate ◽  
Vaccine Dose ◽  
Humoral Response ◽  
Albumin Level ◽  
High Response Rate ◽  
Control Group ◽  
Dialysis Patients ◽  
Serious Adverse Events ◽  
Antibody Levels

Background and objectives: The short-term reported antibody response to SARS-COV-2 vaccination in dialysis patients is high, with a seroconversion response rate up to 97%. Data on the long-term durability of this response are scarce. Our objective was to characterize the long-term anti-spike antibody level in dialysis patients. Design, setting, participants, and measurements: In an observational study, we measured SARS-COV-2 anti-spike antibody levels in dialysis patients who completed 2 doses of the BNT162b2 mRNA SAR S-COV-2 vaccine at 1, 3 and 6 months after the second vaccine dose. We compared the response to dialysis patients who were infected with COVD-19 and to a control group of healthcare-employees. Results: One hundred and forty-two dialysis patients who had been vaccinated (ages 64 ± 11.9 years, 61% male), 33 dialysis patients who had COVID-19 infection (ages 54 ± 14.3 years, 55% male) and 104 individuals in the control group (ages 50 ± 12.2 years, 44% male) were included. The response rate in the vaccinated dialysis patients was 94%, 78% and 73% at 1, 3 and 6 months after the second vaccine dose. In the COVID-19 infected dialysis group and in the control group, the response rate remained at 100% over 6 months. The percentage of change in antibody levels between one and 6 months was −66% in the vaccinated dialysis group, −28% in the control group (p < 0.001) and +48% in dialysis patients who had been infected with COVID-19 (p < 0.001). A non-responder status at 6 months was associated with a lower albumin level. No serious adverse events following vaccination were reported. In conclusion: the initially high response rate to the BNT162b2 vaccine in dialysis patients decreases rapidly. Our results indicate that an early booster (3rd) dose, at three months after the second dose, may be advised for this population to preserve the humoral immunity.

Sign in / Sign up

Export Citation Format

Share Document